Drugs / TV003

Trials 5

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT01782300 Jan 2013 → Mar 2015 dengue disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT01506570 Dec 2011 → Sep 2013 dengue disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT01436422 Aug 2011 → Mar 2014 dengue disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 22 trials
Phase 2 NCT03485144 Dec 2017 → May 2019 dengue disease Medigen Vaccine Biologics Corp. Completed No outcome recorded
Phase 2 NCT02332733 Nov 2014 → Oct 2018 dengue disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Comparator or background therapy1 trial
Phase 2 NCT01696422 Comparator Oct 2013 → Apr 2016 dengue disease Butantan Institute Unknown No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as TV003 “a vaccine (called TV003) against all four types of the dengue virus” NCT02332733 ↗
5

NCT01436422 ↗

NCT01506570 ↗

NCT01696422 ↗

NCT01782300 ↗

NCT03485144 ↗

Known as Admixture TV003 “One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV003” NCT01436422 ↗
Known as TetraVax-DV “TV003(TetraVax-DV), a live attenuated tetravalent dengue vaccine candidate” NCT03485144 ↗
Known as TetraVax-DV Vaccine - Admixture TV003 “TetraVax-DV Vaccine - Admixture TV003” NCT01696422 ↗
1

“TetraVax-DV Vaccine - Admixture TV003” NCT01506570 ↗

Modality Vaccine “live attenuated recombinant TetraVax-DV vaccine” NCT01436422 ↗
Route Subcutaneous “One subcutaneous injection at Day 0 and Day 180” NCT01436422 ↗